Cargando…
Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal
Clinical trials are complicated, time-consuming and costly. From the initial screening, informed consent and recruitment of the participants’ to study completion, the sponsor must undertake a wide array of complex and closely monitored operations, complying with international standards for human sub...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189093/ https://www.ncbi.nlm.nih.gov/pubmed/33524278 http://dx.doi.org/10.1080/21645515.2020.1855955 |
_version_ | 1783705445922242560 |
---|---|
author | Saluja, Tarun Giri, Bishnu Rath Chaudhary, Shipra Tamrakar, Dipesh Kanodia, Piush Palkar, Sonali Vemula, Sridhar Chinaworapong, Suchada Kim, Bomi Gupta, Birendra Prasad Kyoung Jo, Sue Aspinall, Sanet Rai, Ganesh Kumar Steele, Duncan Kim, Jerome H. Wartel, T. Anh Sahastrabuddhe, Sushant |
author_facet | Saluja, Tarun Giri, Bishnu Rath Chaudhary, Shipra Tamrakar, Dipesh Kanodia, Piush Palkar, Sonali Vemula, Sridhar Chinaworapong, Suchada Kim, Bomi Gupta, Birendra Prasad Kyoung Jo, Sue Aspinall, Sanet Rai, Ganesh Kumar Steele, Duncan Kim, Jerome H. Wartel, T. Anh Sahastrabuddhe, Sushant |
author_sort | Saluja, Tarun |
collection | PubMed |
description | Clinical trials are complicated, time-consuming and costly. From the initial screening, informed consent and recruitment of the participants’ to study completion, the sponsor must undertake a wide array of complex and closely monitored operations, complying with international standards for human subject research and local requirements. Conducting these studies in an underdeveloped country, with limited resources, infrastructure, and experience with regulated clinical trials adds to this complexity. The initial site selection, set up and preparatory activities for the clinical trial are crucial to minimizing the risks to both participants and to successful completion during the subsequent study execution. In this paper, we describe the experience and lessons learned of building clinical trial site capacity in terms of infrastructure and human resource development for a Phase III vaccine clinical trial. We believe that sharing the experience of setting up a clinical trial in a resource-limited country will enable other entities contemplating clinical research in these countries, to prepare and plan ahead, to minimize the impact of barriers, and to contribute to bringing more studies to the countries where people live with the burden of vaccine-preventable, poverty-associated diseases. |
format | Online Article Text |
id | pubmed-8189093 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-81890932021-06-17 Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal Saluja, Tarun Giri, Bishnu Rath Chaudhary, Shipra Tamrakar, Dipesh Kanodia, Piush Palkar, Sonali Vemula, Sridhar Chinaworapong, Suchada Kim, Bomi Gupta, Birendra Prasad Kyoung Jo, Sue Aspinall, Sanet Rai, Ganesh Kumar Steele, Duncan Kim, Jerome H. Wartel, T. Anh Sahastrabuddhe, Sushant Hum Vaccin Immunother Commentary Clinical trials are complicated, time-consuming and costly. From the initial screening, informed consent and recruitment of the participants’ to study completion, the sponsor must undertake a wide array of complex and closely monitored operations, complying with international standards for human subject research and local requirements. Conducting these studies in an underdeveloped country, with limited resources, infrastructure, and experience with regulated clinical trials adds to this complexity. The initial site selection, set up and preparatory activities for the clinical trial are crucial to minimizing the risks to both participants and to successful completion during the subsequent study execution. In this paper, we describe the experience and lessons learned of building clinical trial site capacity in terms of infrastructure and human resource development for a Phase III vaccine clinical trial. We believe that sharing the experience of setting up a clinical trial in a resource-limited country will enable other entities contemplating clinical research in these countries, to prepare and plan ahead, to minimize the impact of barriers, and to contribute to bringing more studies to the countries where people live with the burden of vaccine-preventable, poverty-associated diseases. Taylor & Francis 2021-02-01 /pmc/articles/PMC8189093/ /pubmed/33524278 http://dx.doi.org/10.1080/21645515.2020.1855955 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Commentary Saluja, Tarun Giri, Bishnu Rath Chaudhary, Shipra Tamrakar, Dipesh Kanodia, Piush Palkar, Sonali Vemula, Sridhar Chinaworapong, Suchada Kim, Bomi Gupta, Birendra Prasad Kyoung Jo, Sue Aspinall, Sanet Rai, Ganesh Kumar Steele, Duncan Kim, Jerome H. Wartel, T. Anh Sahastrabuddhe, Sushant Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal |
title | Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal |
title_full | Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal |
title_fullStr | Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal |
title_full_unstemmed | Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal |
title_short | Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal |
title_sort | challenges and opportunities in setting up a phase iii vaccine clinical trial in resource limited settings: experience from nepal |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189093/ https://www.ncbi.nlm.nih.gov/pubmed/33524278 http://dx.doi.org/10.1080/21645515.2020.1855955 |
work_keys_str_mv | AT salujatarun challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal AT giribishnurath challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal AT chaudharyshipra challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal AT tamrakardipesh challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal AT kanodiapiush challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal AT palkarsonali challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal AT vemulasridhar challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal AT chinaworapongsuchada challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal AT kimbomi challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal AT guptabirendraprasad challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal AT kyoungjosue challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal AT aspinallsanet challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal AT raiganeshkumar challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal AT steeleduncan challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal AT kimjeromeh challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal AT warteltanh challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal AT sahastrabuddhesushant challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal |